APA (7th ed.) Citation

MK, B., GL, G., KK, J., J, S., JE, G., Ø, S., . . . SW, S. (2022). Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. Journal of internal medicine, 292(3), 477. https://doi.org/10.1111/joim.13495

Chicago Style (17th ed.) Citation

MK, Brun, et al. "Risk Factors for Anti-drug Antibody Formation to Infliximab: Secondary Analyses of a Randomised Controlled Trial." Journal of Internal Medicine 292, no. 3 (2022): 477. https://doi.org/10.1111/joim.13495.

MLA (9th ed.) Citation

MK, Brun, et al. "Risk Factors for Anti-drug Antibody Formation to Infliximab: Secondary Analyses of a Randomised Controlled Trial." Journal of Internal Medicine, vol. 292, no. 3, 2022, p. 477, https://doi.org/10.1111/joim.13495.